Stocks of the Hour: Immutep, Empire Energy, Lincoln Minerals
Immutep (ASX:IMM) has reported promising clinical data from the INSIGHT-003 trial at the ESMO Congress 2023. In response, Immutep CSO, commented, “the compelling data that our proprietary MHC Class II agonist has generated in combination with immune checkpoint inhibitors for NSCLC patients positions efti as one of the more promising clinical candidates in immuno-oncology today.” […]
Stocks of the Hour: Immutep, Empire Energy, Lincoln Minerals Read More »









